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At a glance 
 Hospital emergency data can provide a unique insight into acute health harms related to drug 
use. 
 Euro-DEN Plus uses a sentinel centre model to collect data on emergency department 
presentations with acute drug toxicity; at the time of the latest Euro-DEN Plus meeting in 
Lisbon (end 2018), there were 31 sentinel sites in 21 countries. Before the Euro-DEN project 
started, there was limited systematic collection of data on acute drug toxicity in Europe. 
 There were 23 947 acute drug toxicity presentations reported by the Euro-DEN Plus centres 
over the 4-year period January 2014 to December 2017, representing a median of 0.3 % of all 
emergency presentations to the sentinel hospitals. 
 More than 7 in 10 people presenting with acute drug toxicity arrived by ambulance, which has 
pre-hospital resource implications. 
 Three quarters of those presenting were male, and presentations were most common among 
those aged 20-39 years. 
 Three quarters of patients were discharged directly from the emergency department, and 
almost half were discharged within 4 hours. However, almost 1 in 5 of those discharged from 
the emergency department self-discharged, entailing lost opportunities for brief intervention, 
referral and care in the community. 
 Although only a minority of patients were admitted to hospital, one quarter of those admitted 
required admission to the critical care unit because of severe clinical features. 
 Opioids, and heroin in particular (the latter accounting for 22 % of all presentations), were the 
drugs most frequently encountered in acute drug toxicity presentations. Cocaine and cannabis 
were also prominent; these drugs were involved in 19 % and 17 % of presentations 
respectively. 
 New psychoactive substances (NPS) were seen in 9 % of presentations over the 4-year 
period. There was significant geographical variation in the involvement of NPS in 
presentations, and the type of NPS that was predominant changed from cathinones in 2014-
15 to synthetic cannabinoids in 2016-17. 
 More than one quarter of all presentations involved the misuse of at least one prescription 
medicine, most commonly opioids and benzodiazepines such as methadone, diazepam and 
clonazepam. 
 Presentations with acute drug toxicity constitute a significant burden on emergency health 
services; agitation and aggression are common features, and presentations are more 
common at weekends, in the late evening and at night. 
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Introduction and objective of this report 
There is a significant, multifaceted and rapidly changing social and health burden related to illicit drug 
use in Europe (EMCDDA, 2019). To monitor this phenomenon and to support evidence-based policies, 
data are systematically collected and reported to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on a number of key indicators related to drug use in Europe, including prevalence, 
both among the general population and of problematic forms, admission to treatment, infectious 
diseases and deaths. The data on these epidemiological key indicators are supplemented with 
information from data sources that have been developed in recent years to broaden the scope and 
coverage of the information available. These additional information sources include wastewater analysis 
(EMCDDA, 2016a, 2018a), internet surveys, forensic and pill testing, trendspotter studies (EMCDDA, 
2018b,c) and data on hospital emergencies provided by Euro-DEN Plus (Wood et al. 2014a; Dines et 
al. 2015;, EMCDDA, 2016b). 
The European Drug Emergencies Network (Euro-DEN) was established in October 2013 as a 2-year 
project funded by the European Commission Directorate-General for Justice, with the aim of improving 
knowledge at European level on acute established illicit/recreational drug and new psychoactive 
substance (NPS) toxicity (Wood et al., 2014a). The project has continued with the support of the 
EMCDDA as the Euro-DEN Plus project since April 2015. Euro-DEN Plus has expanded from the 
original 16 sentinel centres in 10 European countries in October 2013. In 2018, there were 31 active 
Euro-DEN Plus sentinel centres collecting data in 21 countries (Figure 1). While two centres (Helsinki in 
Finland and Kaunas in Lithuania) stopped reporting after 2017, three centres (Amsterdam and Utrecht 
in the Netherlands and Bucharest in Romania) started to report data for the year 2018. Active 
recruitment of centres continued in 2019. The methods and added value of the network are described 
below (pages 6-8). 
This report summarises the Euro-DEN Plus data for the 4-year period from 1 January 2014 to 
31 December 2017 from the 32 Euro-DEN Plus centres in 21 countries that were collecting data during 
that period (see Appendix 1). The analysis presented here also draws on scientific presentations 
(references provided on page 30) and round-table discussions at a 2-day meeting of Euro-DEN Plus 
researchers, hosted by the EMCDDA in Lisbon on 4 and 5 December 2018. 
 
  
TECHNICAL REPORT I Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus network 
6 
 
FIGURE 1 
Euro-DEN Plus centres by year of joining, 2013-18 
 
Note: Centres are also located in the non-EU countries of Switzerland (Basel, Bern and Lugano) and Georgia (Tbilisi). 
Abbreviations — KCH, King’s College Hospital, London; STH, St Thomas’ Hospital, London; OAEOC, Oslo Accident and 
Emergency Outpatient Clinic; OUH, Oslo University Hospital. 
 
Methods and added value of the Euro-DEN Plus sentinel system 
Euro-DEN developed a minimum dataset to capture the key demographic, clinical and outcome 
variables in presentations with acute drug toxicity to emergency departments (Wood et al., 2014; 
EMCDDA, 2016b). This dataset currently contains 38 data variables. A purpose-designed Microsoft 
Excel spreadsheet is used to collect these, with pre-formatted variables and drop-down menus to 
ensure consistency. Each centre has appropriate local ethical approval from their institution for the 
collection and sharing of the data. The data are collected on all presentations to each sentinel centre’s 
emergency department with acute drug toxicity. Data are collected from information recorded in medical 
records, and the Euro-DEN Plus data collection sheets are returned every 2 months to the lead centre 
in London for collation and further analysis. 
The recording of the drugs involved in each presentation is based on the patient’s self-report and/or the 
clinical interpretation of the drugs by the clinicians managing the patient and collecting the Euro-DEN 
Plus data in each centre. If drug screening is undertaken as part of routine clinical care, the results of 
the screening are collected, but toxicology investigation is not undertaken specifically for the project. 
This follows international best practice in the management of acute drug toxicity, whereby patients are 
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treated on the basis of the clinical pattern of toxicity and the drugs that the patient reports having used, 
rather than on the basis of analytical confirmation of the drugs involved. 
The criteria used for case definition are set out below. 
 Inclusion criteria: presentations are included if the patient has a history of use or clinical features 
consistent with acute toxicity directly related to illicit drug or NPS use, or if the presentation relates to 
misuse of a prescription/over-the-counter medicine. 
 Exclusion criteria: drug-related presentations are excluded if they are not directly related to acute 
established illicit/recreational drug or NPS toxicity (e.g. cases of trauma, infection or drug 
withdrawal) or are the result of self-harm. Cases of alcohol intoxication on its own are also excluded, 
but data on whether or not alcohol has been co-used in an acute drug/NPS toxicity presentation are 
collected. 
 Of the 16 original Euro-DEN centres, 15 provided data for all 4 years (Roskilde in Denmark was 
unable to collect data in 2017); five additional centres contributed data for 2016 and 2017, and 10 
for 2017 only (Appendix 1). Importantly, the centres have different capacities, catchment areas and 
locations, as described in the appendix to Euro-DEN’s initial report (Euro-DEN, 2015). The number 
of acute drug toxicity presentations per centre in 2017 is illustrated in Figure 2. There were 4 large 
centres with 500 or more presentations in that year, 9 centres with 200-499 presentations, 9 with 
100-199 presentations and 8 smaller centres with fewer than 100 presentations in 2017. 
 The Euro-DEN Plus project monitors, with a high degree of sensitivity, acute drug toxicity 
presentations to sentinel emergency departments across Europe. Previous studies, including 
studies from Euro-DEN Plus, have shown that routine hospital statistics significantly under-represent 
acute drug toxicity presentations; therefore, current national data on acute drug-related harm are 
likely to underestimate the extent of the problem and provide a biased picture (Wood et al., 2011; 
FIGURE 2 
Number of presentations to Euro-DEN Plus centres, 2017  
 
TECHNICAL REPORT I Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus network 
8 
 
Heyerdahl et al., 2014). The enhanced case-based surveillance provided by Euro-DEN Plus yields a 
rich core dataset, enabling analysis of geographical variations and time trends in the drugs involved 
in the presentations and of the patterns of toxicity and the morbidity and mortality associated with 
these presentations. Euro-DEN Plus data reflect local patterns of drug use and drug-related harm, 
providing a powerful and valuable triangulation tool at city level. One limitation of this approach is 
that findings cannot be extrapolated to other cities or to the country in question as a whole. 
However, the expansion of the network to include multiple centres in some countries has helped to 
reduce this limitation. 
The Euro-DEN Plus dataset provides a unique insight into the drugs responsible for acute drug toxicity 
in Europe. It is of particular value given the weaknesses of and limited systematic data from other 
sources on this topic, and has been contributing to EMCDDA-reporting on the drug situation in 
successive European Drug Reports since 2015. It provides a foundation for developing a better picture 
of the overall public health implications of drug use in Europe and helps to fill the gaps in our knowledge 
of the drugs responsible for and the scale of the issues related to acute drug toxicity in Europe. It also 
adds information that can be triangulated with other indicators. Considering the Euro-DEN Plus results 
alongside information from wastewater analysis, general population surveys and web survey data 
enables a greater understanding of the overall public health impact of drug use at population level. 
Euro-DEN Plus 4-year dataset: overview 
Overview of characteristics of acute drug toxicity presentations in Europe 
There were 23 947 acute drug toxicity presentations to the 32 Euro-DEN Plus centres in 21 countries 
over the 4-year period from 1 January 2014 to 31 December 2017. The burden of these acute drug 
toxicity presentations as a proportion of all presentations to emergency departments varied across 
centres. Where the proportion of all emergency department presentations that related to acute drug 
toxicity was known (26 centres), it ranged from 0.1 % to 3.5 % (median 0.3 %; interquartile range, IQR, 
0.2-0.8 %). Overall, 17 066 people presenting with acute drug toxicity (71.3 % of the total) arrived by 
ambulance, which has clear resource implications. 
Demographics 
There was a predominance of males among those presenting in all age groups: 76.2 % of Euro-DEN 
Plus presentations over the 4-year period involved male patients (Figure 3). The majority of those 
presenting were aged 20 to 39 years (67.0 % of presentations); the median age was 31 years (IQR 25-
39 years), with a range of 10-90 years and a modal age of presentation of 25 years. The Euro-DEN 
Plus cohort is several years younger than the population entering drug treatment — although this differs 
depending on the drug involved — and much younger than those who die of an illicit drug overdose (the 
mean age of those dying drug-related deaths in Europe is 39 years) (EMCDDA, 2019). This suggests 
that there are opportunities to intervene in hospital emergency settings, to assess the risk of drug 
problems and to offer brief intervention, harm reduction and referral for drug treatment where 
appropriate. However, the age range of those presenting is wide, and the needs of those older people 
presenting with acute drug toxicity are likely to differ from those of people in the younger age groups. 
This is discussed in more detail in the section ‘Acute drug toxicity presentations among those at 
opposite ends of the age spectrum’, which describes a study highlighting the high proportion of 
presentations related to cannabis among teenagers. 
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FIGURE 3 
Euro-DEN Plus presentations by age and gender, 2014-17 (n = 23 718) 
 
Acute drug toxicity presentations among those at opposite ends of the age spectrum 
While there is global interest in drug use by both younger and older individuals, there are few European 
studies looking specifically at this area and none examining differences in the drugs involved in acute 
toxicity presentations to emergency departments. Euro-DEN Plus data were analysed to describe acute 
drug toxicity presentations among the youngest and oldest age groups, as this information can inform 
prevention and harm reduction strategies targeting people of different ages and at different stages in 
their drug-using history. Presentations reported in the 4-year Euro-DEN Plus dataset were categorised 
into three age groups — (i) 18 years and under, (ii) 19-60 years and (iii) over 60 years — to examine 
the demographics of and drugs used by the two extreme age groups, with the middle age group used 
as a reference comparator. 
Of the 23 947 presentations, 1 384 (5.8 %) were by people aged 18 years or under and 250 (1.0 %) 
were by people aged over 60 years; in 226 presentations (0.9 %), the age was not recorded. The 
proportion of females (36.7 %) was significantly higher in the youngest age group than in the middle 
(23.1 %) and oldest (20.4 %) age groups (p < 0.05 based on a chi-squared test). In the youngest age 
group, the percentages of presentations that involved cannabis (42.2 %), MDMA (15.5 %) and LSD 
(3.8 %) were significantly higher than in the middle age group, whereas in the oldest age group 
significantly more of the presentations involved medicines such as benzodiazepines (38.4 %) and 
opioids other than heroin (18.0 %) (Figure 4). Presentations in both the youngest and oldest groups 
were less likely to involve cocaine or GHB than those in the middle age group. Members of the 
youngest group were also less likely to come to the emergency department by ambulance and more 
likely to be medically discharged from the emergency department (Waring et al., 2020). 
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FIGURE 4 
Proportions of people within each age group reporting each drug in Euro-DEN Plus 
presentations, for selected substances, 2014-17 
 
Note: A presentation can be associated with more than one drug and thus the total for each age group may be greater than 
100 %. The drugs are ordered according to frequency in the middle age group. 
 
 
These differences between the age groups are consistent with data on the prevalence of use in the 
general population, which show a decreasing prevalence of cannabis and MDMA use with age and a 
higher average age of starting using cocaine and heroin. The findings are also consistent with data from 
drug treatment settings and on drug-related deaths, which both point to an ageing cohort of opioid users 
who typically are in their 40s and have problematic use of heroin, other opioids and other medicines 
including benzodiazepines and Z-drugs (EMCDDA, 2019). 
Time-trend analysis shows that, in the 15 centres for which data were available for all 4 years, cannabis 
and benzodiazepines were increasingly involved in presentations in the youngest group over time. 
These initial findings warrant further analysis and triangulation with other datasets, and they also 
illustrate the value of continued monitoring over time. 
More generally, this analysis shows that while, at the individual level, treatment and referral to care may 
essentially be determined by the drug causing the acute toxicity, which drugs are most likely to be 
involved may vary by age. Monitoring and analysis of the demographic characteristics of the 
presentations can reveal findings that have implications for and can inform the design of harm reduction 
activities targeted at different groups. 
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Time patterns in presentations 
As shown in Figure 5, there is seasonal variation in presentations to emergency departments for drug 
toxicity, as well as differences by day of the week and time of day. There were more presentations in 
the summer months (10.2 % of presentations were in August) than in the winter months (6.6 % of 
presentations were in February). During the week, a greater proportion of presentations per day were 
seen at the weekend (17.7 % and 17.5 % of presentations occurred on a Saturday and on a Sunday 
respectively) than on other days of the week (12.4 % to 14.1 % occurred per day from Monday to 
Friday). Presentations were also more common in the evening and in the early hours of the morning 
than during ‘core’ working hours, which has important implications for the staffing of emergency 
departments for the management of these presentations. Taken as a whole, these time patterns in 
presentations to the emergency department with acute drug toxicity suggest that a significant proportion 
of presentations relate to recreational patterns of drug use, which are more common at these times. 
FIGURE 5 
Proportions of presentations to the Euro-DEN Plus centres by time of the day (top), day of the 
week (bottom left) and month of the year (bottom right), 2014-17  
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Drugs involved in emergency department presentations 
The majority of the 23 947 presentations over the 4 years of data collection involved one (63.4 %) or 
two (25.7 %) drugs; only 8.0 % involved three drugs; and 2.9 % involved four or more. Overall, there 
was a mean of 1.5 drugs (standard deviation, SD, ± 0.8 drugs) (excluding alcohol) per presentation. 
Whether or not alcohol was involved in the presentation was not recorded in a little under one third of 
presentations; in the 16 860 presentations (70.4 % of the total) for which this information was recorded, 
alcohol had been used in 59.0 %. 
Drug categories 
As shown in Figure 6, the drugs involved in the presentations were predominantly established illicit 
drugs (66.9 % of drugs identified in presentations) or prescription/over-the-counter (OTC) medicines 
(23.0 %). It is important to note that prescription/over-the-counter medicines are included only if the 
presentation involved misuse of the drugs. NPS accounted for only 6.2 % of the drugs involved in the 
presentations. When comparing years, it is important to remember that the centres reporting varied 
from year to year, which may have had an impact on the substances involved in presentations because 
of geographical variations in drug use. 
  
FIGURE 6 
Frequency distribution of the main drug groups among all drugs identified in  
Euro-DEN Plus presentations, 2014-17 
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Top 20 drugs 
Overall, heroin, cocaine, cannabis, GHB/GBL, amphetamine and MDMA are the most frequently 
reported drugs (Figure 7). This reflects both the health risks associated with use of these drugs (heroin 
in particular) and also the high prevalence of use (for cocaine and cannabis). GHB/GBL is the fourth 
most frequently reported drug, although, according to the available data, the prevalence of its use in the 
general population is low. However, it is important to note that most cases are reported by one London 
centre. This centre serves an extensive area of nightlife activity, where the drug is more commonly 
used, and this is reflected in the type of acute toxicity episodes seen in the centre. Amphetamine and 
MDMA are the fifth and sixth most frequently reported drugs, but, as with other drugs, their frequency 
varies by centre. 
Of the 20 most frequently reported drugs, 4 are benzodiazepines (clonazepam, ‘benzodiazepine 
unknown or unspecified’, diazepam and alprazolam), with a total of 3 513 reports, and clonazepam is 
the seventh most frequently reported drug (Figure 7). This shows the importance of this group of 
medicines with regard to drug-related acute poisonings. Other medicines, including methadone but also 
pregabalin and zopiclone, are frequently reported as well. Two NPS feature in the list of the most 
frequently identified drugs: mephedrone and synthetic cannabinoids. 
The profiles of acute toxicity presentation vary by hospital, as described later in this report with a focus 
on four large centres that represent half of all presentations in 2017 (see ‘Geographical variation and 
city profiles’, page 19). This complements and provides local-level insights into the top 20 drugs for the 
4-year dataset shown in Figure 7. 
  
FIGURE 7 
Top 20 drugs involved (number of reports) in Euro-DEN Plus presentations, 2014-2017 
 
Note: Out of 36 232 drugs reported (excluding alcohol) involved in 23 947 presentations. 
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FIGURE 8 
Number of presentations involving selected drugs to the 15 Euro-DEN Plus sentinel hospitals 
that have reported data since 2014 
An analysis of trends in the most common substances seen in the 15 centres reporting data for all 
4 years from 2014 to 2017 (Figure 8) shows a variety of trends: reports of heroin declined over the 
whole period (but with perhaps early signs of flattening out in 2017); reports of cocaine powder and 
cannabis declined slightly up until 2016 but then increased in 2017; reports of crack cocaine and 
methamphetamine declined or were stable early on but have increased since 2015; reports of 
GHB/GBL, amphetamine and MDMA have fluctuated year on year but have overall remained fairly 
stable. These findings are consistent with other indicators suggesting a rebound in the powder and 
crack cocaine market and associated use and harm over recent years in Europe (EMCDDA, 2018c); 
with regard to heroin, this change is consistent with other indicators on treatment demand (EMCDDA; 
2019). 
In the following subsections, more detailed consideration is given to patterns of presentations for NPS, 
prescription medicines, MDMA, cocaine and GHB/GBL. These substances were the subject of 
contributions at the 2018 Euro-DEN Plus meeting in Lisbon in December 2018, and those contributions 
have been used as the basis of the analysis included in this report. 
New psychoactive substances 
Overall, NPS were involved in only 9.1 % of all 23 947 presentations (accounting for 6.2 % of all drug 
identifications), but there was significant geographical variation, with 6 centres reporting no 
presentations involving an NPS, 16 centres reporting less than 5 % of presentations involving an NPS 
and 6 centres reporting more than 20 % of presentations involving an NPS. 
The two most common categories of NPS involved in the presentations were cathinones and synthetic 
cannabinoids; however, as shown in Figure 9, among the 15 centres reporting data for all 4 years from 
2014 to 2017, these presentations were concentrated in a small number of centres, with only 7 centres 
reporting presentations involving mephedrone (the most commonly reported cathinone, involved in 
71.1 % of all cathinone presentations) and 9 centres reporting presentations involving synthetic 
cannabinoids. London, Dublin and York reported most mephedrone presentations, while London, 
Gdańsk and Munich reported most synthetic cannabinoid cases. There was an overall shift towards a 
decrease in the number of mephedrone cases and an increase in the number of synthetic cannabinoid 
cases from 2014 to 2017. The shift was visible mainly in the two London centres and — although the 
numbers were smaller — in the Gdańsk centre (Figure 9). 
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FIGURE 9  
Presentations related to mephedrone (left) and synthetic cannabinoids (right) in the 15 hospitals 
that reported every year from 2014 to 2017 
 
 
Note: KCH, King’s College Hospital; OAEOC, Oslo Accident and Emergency Outpatient Clinic; STH, St Thomas’ Hospital. 
 
There was a significant change in the proportions of presentations involving these two NPS categories 
over the 4-year period. In 2014, 76.9 % (400) of the 520 NPS presentations involved a cathinone, with 
only 5.4 % involving a synthetic cannabinoid; conversely, in 2017 only 17.2 % (82) of the 476 NPS 
presentations involved a cathinone, while 69.5 % involved a synthetic cannabinoid. The number of 
presentations related to synthetic cannabinoids increased markedly from 28 cases in 2014 to 228 cases 
in 2017 among the 15 centres reporting data for all 4 years from 2014 to 2017 (Figure 9). While these 
two substances are plotted together, it is not likely that the change in NPS involved in Euro-DEN Plus 
presentations relates to the same population switching NPS, particularly as there has been a change in 
the geographical distribution of presentations (Figure 9). It is more likely that this relates to differences 
in the NPS used among different sub-populations, with use of synthetic cannabinoids more common 
among those who are socially marginalised, for instance prisoners and homeless drug users. 
Prescription medicines 
Some prescription and over-the-counter registered medicines (hereafter referred to as prescription 
medicines) have potential for misuse. They are included in the Euro-DEN Plus dataset only if they are 
identified as having been misused and involved in Euro-DEN Plus presentations. 
Of the 23 947 presentations in the 4-year Euro-DEN Plus dataset, 6 207 (25.9 %) involved at least one 
prescription medicine, and of these almost half (2 876; 46.3 % — 12 % of all presentations) involved 
only prescription medicines, with no other established illicit/recreational drug or NPS. The people 
presenting with toxicity in which only prescription medicines were involved were slightly older (median 
age 34 years, IQR 28-43 years) than those presenting overall (median age 31 years, IQR 25-39 years), 
and the proportion of women was higher (31.6 % in the prescription-only group, compared with 23.8 % 
for all Euro-DEN Plus presentations). There was considerable variation between Euro-DEN Plus 
centres in the proportion of presentations involving only prescription medicines, with these making up 
less than 10 % of presentations in nine countries (Belgium, Bulgaria, Italy, Malta, Poland, Slovakia, 
Spain, Switzerland and the United Kingdom) and more than 25 % of presentations in five countries 
(Czechia, Estonia, Finland, Germany and Latvia). 
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There were 209 different prescription medicines involved in Euro-DEN Plus presentations; the most 
common were benzodiazepines (51.3 % of the 2 876 presentations involving only prescription 
medicines and 6.3 % of all 23 947 Euro-DEN Plus presentations), opioids (50.1 % and 6.1 %), Z-drugs 
(9.8 % and 1.2 %) and GABA-ergic drugs (7.3 % and 0.9 %) (Figure 10). 
MDMA 
The MDMA market in Europe has changed in recent years, and there has been an increase in higher-
dose pills and concentrated powders (EMCDDA, 2016c, 2019). The characteristics of and changes in 
presentations involving MDMA to Euro-DEN Plus over the 4 years from 2014 to 2017 need to be viewed 
in this context. Overall, over this period, 2 013 (8.4 %) of the 23 947 Euro-DEN Plus presentations 
involved MDMA. The proportion of presentations involving MDMA varied across the centres, from over 
10 % in Belgium, Czechia, Denmark, France, Slovakia and the United Kingdom to less than 5 % in 
Bulgaria, Finland, Germany, Latvia, Lithuania, Norway and Poland. 
On average, those who presented with MDMA-related acute toxicity tended to be younger and were 
more likely to be female: the median age of those presenting with MDMA-related toxicity was 24 years 
(IQR 20-29 years), compared with 32 years (IQR 25-40 years) for the overall dataset, and 28.7 % were 
female, compared with 23.8 % in the overall dataset. Almost all MDMA intoxications occurred in the 
context of polysubstance use; only 4.4 % of presentations involving MDMA involved use of MDMA 
alone, whereas 36.4 % of all presentations in the dataset involved use of one substance on its own. In 
the cases associated with polysubstance use, alcohol was by far the most common substance co-
ingested with MDMA (70.4 % of MDMA presentations involving other substances), followed by cocaine 
(25.6 %), cannabis (14.6 %), amphetamine/methamphetamine (14.1 %), benzodiazepines/Z-drugs 
(7.2 %), GHB/GBL (6.8 %) and ketamine (5.3 %). Acute MDMA toxicity was characterised by 
sympathomimetic effects: agitation/aggression (32.7 %), anxiety (26.4 %), palpitations (14.1 %), 
hypertension (8.8 %), chest pain (8.5 %) and hyperthermia (2.4 %) (Noseda et al., 2020). 
FIGURE 10 
Top 20 prescription medicines involved in ‘any prescription medicine’ presentations (left) and 
‘prescription medicine only’ presentations (right), Euro-DEN Plus, 2014-17 
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When the presentations to the 15 centres that reported data for all 4 years are considered, the overall 
proportion of MDMA presentations remained constant between 2014 and 2015 (8.2 % and 8.3 % 
respectively), increased to 10.4 % in 2016 and returned to 8.2 % in 2017 (see Figure 8). 
Powder cocaine and crack cocaine 
In recent years, there have been indications of increasing cocaine availability in Europe as well as 
pockets of increasing crack cocaine use in some parts of the region (EMCDDA, 2018c). An in-depth 
study of the 17 371 Euro-DEN Plus presentations between October 2013 and December 2016 found 
that 3 002 (17.3 %) involved cocaine (powder cocaine, 2 600; crack cocaine, 376; both, 26) (Miró et al., 
2019). The demographics, the clinical picture and emergency department management for these 
presentations were analysed, and the clinical features seen in the powder and crack cocaine 
presentations were compared using multivariate adjustment to control for the co-ingestion of alcohol 
and other drugs. 
Overall, the people presenting with acute toxicity associated with cocaine use had a mean age of 
32 years (SD ± 9 years) and 23 % were female. The proportion of presentations involving cocaine 
varied significantly between countries (> 30 % of presentations in Denmark, France, Malta and Spain), 
and only centres in France, Ireland, Malta, Poland and the United Kingdom reported crack cocaine 
cases. There were differences in the drugs that were co-ingested with powder cocaine and with crack 
cocaine and in the clinical features of the presentations involving these two substances (Table 1). 
Patients who presented with crack cocaine toxicity were more likely to have used other drugs, 
particularly opioids, while they were less likely to have ingested alcohol. 
TABLE 1 
Numbers of cases with and frequencies of (i) co-ingestion of certain substances and (ii) 
occurrence of certain clinical features, for presentations related to powder cocaine and crack 
cocaine (Euro-DEN Plus presentations between October 2013 and December 2016) 
 All presentations 
involving cocaine 
n = 3 002 (%) 
Powder 
cocaine 
n = 2 600 (%) 
Crack 
cocaine 
n = 376 (%) 
Adjusted odds 
ratio; 95 % 
confidence interval 
Co-ingestion     
Co-ingestion of alcohol  1 759 (58.6) 1 557 (59.8) 189 (50.3)  
Co-ingestion of any other drug 
(apart from alcohol and 
cocaine) 
 1 705 (56.8) 1 431 (55.0) 248 (66.0)  
Amphetamine and related 
substances 
 581 (19.4)  574 (22.1)  7 (1.9)  
Opioids  566 (18.9)  394 (15.2) 172 (45.7)  
Clinical features     
Hypotension (systolic blood 
pressure < 80 mmHg) 
 110 (3.9)  86 (3.5)  23 (7.1) 2.35; 1.42-3.89 
Bradypnoea (respiratory 
rate < 12/minute) 
 80 (3.8)  58 (3.2)  22 (7.8) 1.81; 1.03-3.16 
Hypertension (systolic blood 
pressure > 180 mmHg) 
 44 (1.7)  32 (1.4)  12 (3.8) 2.59; 1.28-5.25 
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 All presentations 
involving cocaine 
n = 3 002 (%) 
Powder 
cocaine 
n = 2 600 (%) 
Crack 
cocaine 
n = 376 (%) 
Adjusted odds 
ratio; 95 % 
confidence interval 
Anxiety  868 (32.2)  809 (32.4)  57 (17.6) 0.51; 0.38-0.70 
Chest pain  500 (17.6)  467 (18.7)  30 (9.3) 0.47; 0.31-0.70 
Palpitations  476 (16.7)  445 (17.8)  31 (9.6) 0.57; 0.38-0.84 
Vomiting  261 (9.7)  244 (9.8)  17 (5.3) 0.54; 0.32-0.90 
Tachycardia 
(heart rate > 100 bpm) 
 1 107 (40.9) 1 015 (42.9) 87 (27.59) 0.51; 0.39-0.67 
 
Sedative drugs were given in 29.3 % of presentations involving cocaine. The median length of hospital 
stay was 4 hours and 2 minutes; 22.1 % of patients were admitted to hospital from the emergency 
department; and 0.4 % (n = 12) died (all of whom had powder cocaine-related toxicity). 
GHB/GBL 
GHB/GBL is among the most frequently reported drugs in the Euro-DEN Plus dataset, involved in 
13.1 % of presentations, although most cases were from just two or three centres. An analysis of the 
differences in the clinical manifestations produced by intoxication with GHB/GBL alone and in 
combination with other substances, based on the data from the first year of the project (October 2013 to 
September 2014) (Miró et al., 2017), found that in the 710 GHB/GBL presentations reported the most 
frequently co-ingested substances were alcohol (50 % of presentations), amphetamines (36 %), 
cocaine (12 %) and cannabis (8 %). The three most frequently identified clinical features were altered 
behaviour (39 %), reduced consciousness (34 %) and anxiety (14 %). The severity ranged from mild 
cases requiring no treatment (43.4 %) to severe cases requiring admission to intensive care (14.6 %) 
and mechanical ventilation (6.9 %). No deaths were reported. In comparison with presentations 
involving GHB/GBL alone, the GHB/GBL presentations involving other substances (alcohol or drugs) 
were more likely to involve vomiting (15 % versus 3 %, p < 0.001) and ‘other cardiovascular features’ 
(e.g. palpitations, chest pain, arrhythmias) (5.3 % versus 1.5 %, p < 0.05), a greater need for treatment 
(59.8 % versus 48.3 %, p < 0.01) and a longer length of hospital stay (> 12 hours, 11.3 % versus 3.6 %, 
p < 0.01). 
The clinical impact of the co-ingestion of alcohol in those with acute GHB/GBL toxicity was also studied 
using Euro-DEN Plus data for the period October 2013 to December 2016 (Galicia et al., 2019). Of the 
17 371 Euro-DEN Plus presentations in this period, 2 349 involved GHB/GBL. Whether or not alcohol 
was involved was known for 1 882 of these presentations. While 1 273 of these involved GHB/GBL and 
other drugs, the remaining 609 presentations involved no drug other than GHB/GBL. Of these, 183 
involved GHB/GBL alone and 426 involved GHB/GBL with alcohol. Presentations involving co-ingestion 
with alcohol generally related to younger patients than those involving GHB/GBL alone, and these 
patients were more likely to arrive at the emergency department by ambulance (86.6 % versus 68.3 %, 
p < 0.001) and less likely to have bradycardia (15.7 % versus 23.5 %, p = 0 027) and/or a reduced level 
of consciousness (Glasgow Coma Score < 13 points, 58.9 % versus 49.1 %, p = 0.031). Those 
presenting with alcohol co-ingestion were also more likely to receive treatment (60.4 % versus 49.2 %, 
p = 0.011) — specifically sedatives (20.1 % versus 12.8 %, p = 0.034) — be admitted to critical care 
(55.3 % versus 22.4 %, p < 0.001) and have a hospital stay lasting longer than 6 hours (28.4 % versus 
16.9 %, p = 0.003). 
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Geographical variation and city profiles 
There is geographical variation in the proportions of presentations involving the main drug groups 
across the Euro-DEN Plus centres (Figure 11 and Appendix 2). The geographical patterns found in 
presentations related to stimulants reflect those found in other indicators such as the prevalence of use 
of stimulants reported in general population surveys and other indicators (e.g. web surveys and 
wastewater analysis), as reported in the European Drug Report 2019 (EMCDDA, 2019). Amphetamines 
are most common in the north and east of Europe, whereas presentations related to cocaine are 
predominant in the south and west of Europe (EMCDDA, 2019). 
In addition to this geographical variation seen across countries, there are also differences between 
Euro-DEN Plus centres that may reflect variations in hospital catchment areas and local patterns of use, 
for example, the NPS trends discussed on page 15. 
 
FIGURE 11 
Frequencies of cocaine, amphetamine and methamphetamine presentations (percentage of 
presentations), aggregated by country, 2017 
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Beyond age and gender, the profiles of those presenting with drug acute toxicity vary, as illustrated by 
the data from the centres with the largest numbers of cases: Oslo Accident and Emergency Outpatient 
Clinic (OAEOC); Dublin; London, St Thomas’ Hospital (STH); and Antwerp. In Oslo and Dublin, heroin 
is the drug primarily involved. In both centres, a stimulant was the second most frequently reported 
drug, but the drug involved differed: amphetamine in Oslo and cocaine in Dublin. Both sites had 
medicines as the third most frequently involved drug: clonazepam in Oslo and zopiclone in Dublin. 
Other depressant drugs (methadone, other prescription opioids and benzodiazepines) and other 
medicines were also frequently reported in both centres. In contrast, London STH and Antwerp reported 
primarily stimulant and recreational drugs. GHB/GBL, cocaine and synthetic cannabinoids were 
predominant in London STH, while cocaine, cannabis and amphetamines were the most common drugs 
in Antwerp (Figure 12). 
FIGURE 12 
Gender and main drugs involved in the presentations in selected centres, Euro-DEN Plus, 2017 
Oslo OAEOC — median age 33 years (IQR 27-42 years); Dublin — median age 31 years (IQR 25-38 years); London STH — 
median age 32 years (IQR 26-40 years); Antwerp — median age 32 years (IQR 25-39 years). 
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Clinical features 
Data are collected for all Euro-DEN Plus presentations on whether or not the patients develop pre-
defined clinical features during their hospital stay (Wood et al., 2014a). Figure 13 shows the proportion 
of patients who developed certain symptoms and/or had these or other abnormal physiological 
symptoms on presentation. As several features may be reported for one presentation, the totals are 
greater than the total number of presentations. While the clinical features are drug-dependent, as could 
be seen above with regard to powder cocaine, crack cocaine and GHB, the most commonly reported 
features overall were tachycardia (heart rate > 100 bpm) on presentation, agitation and anxiety, all 
associated with stimulant toxicity; these were each recorded in over 20 % of presentations. Severe 
clinical features including coma, psychosis, seizures and arrhythmias were less frequent, seen in 5-
10 % of presentations; however, these are important, as they have implications for service organisation 
and resourcing. Agitation and psychosis can be particularly problematic in patients with acute drug 
toxicity, requiring the involvement of several members of staff. 
Most of those presenting (54.6 %) received some active treatment over and above observation; data 
are collected on five types of treatment (sedation, intubation, naloxone (antidote to opioids), flumazenil 
(antidote to benzodiazepines) and ‘other antidotes’). Of these, the most common were sedation (39.5 % 
of those treated) and naloxone (29.3 %); of those receiving naloxone, two thirds received it in the pre-
hospital setting. Smaller proportions were intubated (6.1 % of those treated) or received flumazenil 
(3.9 %). 
Synthetic cannabinoids versus cannabis: a comparison 
Synthetic cannabinoids are the largest group of NPS reported to the EMCDDA European Early Warning 
System (EMCDDA and Europol, 2019), and numerous recent case reports and small case series have 
confirmed the potential for severe toxicity, including fatalities, associated with the use of second and 
particularly third-generation synthetic cannabinoids. As shown above (see page 15), synthetic 
cannabinoid reports increased within the Euro-DEN Plus dataset, and they became the NPS most 
commonly involved in Euro-DEN Plus presentations in 2016 and 2017. Only one previous study has 
compared acute synthetic cannabinoid and acute cannabis toxicity presentations; this study was limited 
FIGURE 13 
Clinical effects reported in presentations to Euro-DEN Plus centres, 2014-17 
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by its small size (17 presentations involving a synthetic cannabinoid) and the presence of co-ingestants 
(Zaurova et al., 2016). 
The demographic and clinical characteristics of Euro-DEN Plus presentations involving synthetic 
cannabinoids and cannabis were compared. Cannabis was involved in presentations to all 31 Euro-
DEN Plus centres, with 4 153 presentations (17.3 % of all presentations) during the 4-year period 
between 1 January 2014 and 31 December 2017. In comparison, synthetic cannabinoids were involved 
in 737 presentations (3.1 % of all presentations) to only 13 centres (42 % of all centres) over the 4-year 
period. The majority of the presentations involving a synthetic cannabinoid were seen in the Euro-DEN 
Plus centres in the United Kingdom and Malta; these presentations accounted for over 80 % of all Euro-
DEN Plus synthetic cannabinoid presentations. 
The most commonly co-used substance for both cannabis and synthetic cannabinoids was cocaine, 
which was associated with 63 % of synthetic cannabinoid receptor agonist (SCRA) cases and with 34 % 
of cannabis cases. Amphetamine was associated with 21 % of SCRA cases and 20 % of cannabis 
cases. In contrast to cocaine, heroin was more likely to be involved in polydrug cannabis presentations 
(15 % of cases) than in polydrug synthetic cannabinoid presentations (5 %). Excluding alcohol, 
cannabis was reported as the only substance in 49 % of cannabis presentations, whereas synthetic 
cannabinoids, when reported, were more commonly the only drug involved (82 % of the 737 
presentations involving a synthetic cannabinoid involved only a synthetic cannabinoid). Cannabis and 
synthetic cannabinoids were reported together in only 54 presentations over the 4-year period. 
Preliminary findings demonstrate different demographics and clinical characteristics for cannabis-only 
and synthetic cannabinoid-only presentations. Among the cannabis presentations, 76 % involved 
males, compared with 88 % of the SCRA presentations, while the mean age was 28.8 years (SD 
± 10.6 years) for cannabis and 32.0 years (SD ± 10.8 years) for synthetic cannabinoids. Clinical 
characteristics were different too. The most frequently observed clinical features among the synthetic 
cannabinoid-only presentations were agitation (52 %), anxiety (23 %), vomiting (21 %) and 
hallucinations (15 %). For cannabis-only presentations, anxiety (39 %), agitation (22 %), vomiting 
(22 %) and palpitations (20 %) were the most common clinical features (Figure 14). These findings on 
cannabis-only presentations over 4 years were consistent with the findings of an earlier analysis of the 
Euro-DEN cases, which showed that agitation, aggression and anxiety were prominent clinical features 
(Dines et al., 2015b). Those presenting with synthetic cannabinoid toxicity were more likely to arrive by 
ambulance, to present with seizures and to require intubation. Furthermore, presentations involving 
synthetic cannabinoids more frequently resulted in admission to hospital or self-discharge from the 
emergency department than presentations involving only cannabis. 
FIGURE 14 
Most frequently observed clinical features among Euro-DEN Plus presentations involving only 
synthetic cannabinoids and Euro-DEN Plus presentations involving only cannabis, 2014-17 
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Outcomes 
Discharge from the emergency department 
Three quarters (76 %) of patients were discharged directly from the emergency department; the 
majority were medically discharged and 17.1 % were self-discharged (Figure 15 and ‘Self-discharge in 
the Euro-DEN Plus dataset’, below). Of the 5 778 patients admitted, 24.8 % went to critical care 
because of severe clinical features and 4.5 % went to a psychiatric ward. 
The length of hospital stay is defined as the time from presentation to the emergency department to 
discharge from the hospital. As shown in Figure 15, 88.9 % of presentations were discharged within 
24 hours. Overall, the median length of stay was 4 hours 45 minutes (IQR 2 hours 34 minutes to 
9 hours 59 minutes), and the range was 2 minutes to 206 days. 
Self-discharge in the Euro-DEN Plus dataset 
Self-discharging patients leave the medical facility against medical advice or before seeing a doctor. 
This has significant clinical implications, as some of these patients are likely to need longer observation 
or specific treatment. It also entails missed opportunities to offer brief interventions or identify patients 
for possible referral to community services. In the 4-year dataset, 4 098 (17.1 %) of the 23 947 
presentations self-discharged from the emergency department. There were large variations in self-
discharge rates between the centres, with the highest reported by the Munich centre (66.4 %), Prague, 
Dublin, Gdańsk and Kaunas, where more than one quarter of presentations were self-discharged. 
There were no self-discharging patients at the centres in Sofia and Tbilisi, and less than 1 in 10 patients 
discharged themselves from the centres in Tallinn, Barcelona, Oslo (Oslo University Hospital), Riga, 
Lugano, Pärnu, Mallorca, Bern, Antwerp, Ghent, Bratislava, London (King’s College Hospital) and Basel 
(Vallersnes et al., 2020). 
 
FIGURE 15 
Outcome of presentation (left) and length of hospital stay (right), Euro-DEN Plus presentations, 
2014-17 
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Deaths 
There were 101 deaths reported (deaths were recorded if they occurred after presentation to the 
emergency department and before discharge from hospital), giving an overall fatality rate of 0.4 %. Of 
these deaths, 47 occurred within the emergency department and 54 after admission to hospital; 32 of 
the deaths occurred 24 hours or more after hospital presentation. 
The majority of patients who died — 68 of 101 patients (67.3 %) — arrived in the emergency 
department in cardiac arrest. Most (74, or 73.3 %) of the deaths were in males, which is consistent with 
the sex profile of the presentations, and the median age at death was 36 years (IQR 30.0-41.5 years, 
range 18-63 years); those who died were slightly older than the cohort as a whole (median age 
31 years, IQR 25-39 years). This could be because of the predominance of opioids and heroin in 
presentations that result in death. 
The drugs most commonly involved in deaths were opioids (53 deaths; including 25 with heroin and 15 
with methadone) and stimulants (31 deaths; most commonly involving cocaine, amphetamine or 
MDMA). NPS were involved in 10 deaths, and the most common NPS was mephedrone, which was 
involved in 5 deaths. A synthetic cannabinoid was reported in only one death (in combination with 
methadone). 
Seizures: drugs responsible and clinical importance 
Seizures are a recognised and potentially serious complication of recreational drug use. An analysis 
was conducted that compared Euro-DEN Plus presentations with and without seizures and estimated 
seizure incidence for different drugs involved in presentations in which no other drug was involved 
(regardless of whether alcohol was present or not) (Wolfe, 2019). 
In the 23 947 presentations between January 2014 and December 2017, there were 1 013 reported 
seizures (4.2 %). The demographics were similar for those with and those without seizures. With 
respect to other clinical features and outcomes, coma (odds ratio, OR, 3.34, 95 % confidence interval, 
CI, 2.82-3.96, p < 0.01), cardiac arrest (OR 2.16, 95 % CI 1.16-4.02, p = 0.001), arrhythmias (OR 2.38, 
95 % CI 1.56-3.56, p <0.001), intubation (OR 5.56, 95 % CI 4.56-6.77, p < 0.001), critical care 
admission (OR 4.22, 95 % CI 3.58-4.99, p < 0.001) and death (OR 2.27, 95 % CI 1.24-4.53, p = 0.002) 
were more common in the seizure group. There were significant associations between several drugs 
and seizure incidence, most notably fentanyl and synthetic cannabinoids; other drugs were associated 
with a lower seizure incidence, including heroin, clonazepam and cannabis. 
Validity of Euro-DEN Plus data and complementarity with key indicator datasets 
Self-report versus analytical confirmation (immunoassay and confirmatory screening) 
The drugs involved in Euro-DEN Plus presentations are identified based on the patient’s self-report and 
information recorded in the patient’s notes by the treating physician. Only a minority (around 15-20 %) 
of presentations involve analytical toxicology tests being undertaken; this reflects routine clinical 
practice. When analytical toxicology is undertaken, this may involve immunoassay (bedside or 
laboratory) or confirmatory mass-spectrometry analyses, depending on hospital routines, resources and 
available equipment. 
The use of analytical testing was examined to explore the extent of agreement between test results and 
self-reporting. The findings of immunoassays compared with those of the less available but more 
specific confirmatory mass-spectrometry analyses, using Euro-DEN Plus data for the period from 
October 2013 to September 2015 (Liakoni et al., 2018). During this period, 1 674 (15.3 %) of the 10 956 
presentations resulted in a ‘drugs of abuse’ test being performed. In 213 (12.7 %), both an 
immunoassay and a mass-spectrometry test were performed. Generally, there was a high degree of 
agreement between the self-reported drugs used and the analytical toxicology results; this was 
particularly the case for commonly used illicit drugs, such as heroin and cocaine (Liakoni et al., 2018). 
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NPS could be detected only with mass spectrometry. For amphetamine-type substances, including 
classic amphetamines, mass spectrometry is more sensitive than immunoassay. In contrast, 
immunoassay performed well for cannabis (THC), cocaine and methadone. 
An additional analysis was performed looking at the toxicological analyses undertaken in 2 688 (18.8 %) 
of the 14 330 Euro-DEN Plus presentations between October 2015 and December 2017 (Liakoni et al., 
2018). Mass spectrometry was available in addition to immunoassay in 11 centres, while 6 centres used 
only immunoassay. Again, the analytical findings largely confirmed the self-reported drugs. This was the 
case in 95 % of cases involving a drug declared to be cocaine, 91 % for heroin, 89 % for cannabis, 
78 % for sedatives and 60 % for amphetamines. Amphetamines and NPS (cathinones and synthetic 
cannabinoids) were detected relatively more frequently in centres where mass spectrometry was 
available than in centres that had immunoassay only. Cannabis (THC), cocaine and opioids (heroin) 
were detected reliably with immunoassay alone. 
These analyses confirm that patient self-reporting of the drugs used in acute toxicity presentations to 
the emergency department is reliable, particularly for established illicit drugs; further work is required to 
determine the value of self-reporting in NPS-related cases. 
Euro-DEN Plus coding and ICD-10 projects 
Previous studies have shown that there is limited systematic collection of data on acute drug-related 
harm in Europe (Heyerdahl et al., 2014). Information at national level on healthcare resource utilisation 
related to acute illicit drug toxicity generally relies on collated hospital admissions data. Typically, these 
data are classified using the International Classification of Diseases version 10 (ICD-10) coding system, 
and previous studies have shown that this approach has serious limitations for acute drug toxicity 
presentations and significantly underestimates presentations (Wood et al., 2019). To better understand 
the scale of the underestimation and to explore the possibilities of using available healthcare data, a 
mapping exercise was conducted across 29 of the Euro-DEN Plus centres in November 2018, to 
describe the coding of presentations related to acute drug toxicity. The majority of centres (22) used 
ICD-10 for coding, with smaller numbers using ICD-9, the 4th edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV), DSM-V, SNOMED or other coding systems. Among the centres 
studied, 19 coded all presentations, whereas 10 coded only cases that resulted in admission to hospital; 
83 % identify both primary and subsequent codes for each presentation, with 17 % identifying only the 
primary diagnostic code. Typically, coding was done within a week of a presentation in 75 % of centres, 
and a variety of sources were used to find information to enable coding to be undertaken (medical and 
nursing notes in 28 centres, discharge summaries in 19 centres and investigations in 14 centres). 
Previous work to identify deficiencies in the coding of acute toxicity (Wood et al., 2011, 2019) reviewed 
the coding of 619 presentations to three Euro-DEN Plus centres that use ICD-10 for their primary 
coding. Only 34 % (213 presentations) were coded, with variability in the proportion that received a 
primary ICD-10 code that related to drug toxicity (100 %, 18.9 % and 9.6 %). Overall, when a 
presentation was coded, the recording of the use of a drug was very good, with 90 % receiving a 
primary or secondary ICD-10 code that related to drug toxicity, with coding better for more frequently 
used drugs. 
Previous studies in the United Kingdom (Wood et al., 2011; Shah et al., 2011) and qualitative feedback 
from the Euro-DEN Plus mapping exercise have demonstrated that ICD-10 coding poorly captures the 
true healthcare resource utilisation related to the use of illicit drugs and NPS. This is due to a number of 
factors, including (i) a lack of ICD-10 codes for a range of established drugs (e.g. MDMA); (ii) the fact 
that the majority of NPS have emerged many years after the ICD-10 codes were finalised; (iii) the fact 
that presentations are coded based on clinical features rather than the drug involved (e.g. cocaine-
induced chest pain is coded as chest pain rather than cocaine use); (iv) the fact that, in some countries, 
only those presentations that result in admission to hospital are coded, with cases in which the patient 
is discharged directly from the emergency department not coded; and (v) the fact that, in some 
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countries only the primary codes applied are recorded, and not subsequent codes that may indicate 
drug use. 
Future work is planned by Euro-DEN Plus to further understand the deficiencies in the current (i.e. ICD-
10) and proposed (e.g. ICD-11) coding systems. A revision (ICD-11) of the current International 
Classification of Diseases coding system has been proposed, which is currently in draft form and 
awaiting final approval from the World Health Organization, prior to its wider roll-out and 
implementation. This revised ICD-11 coding system has an increased number of drugs and drug 
classes mentioned by name, as well as including a range of NPS. 
The ultimate aim of this work is to inform the development of a tiered acute harm data collection model, 
with high-level resolution and detailed data from the Euro-DEN Plus sentinel centres, complemented by 
lower level background data from routine hospital coding across all or at least a much larger number of 
hospitals. 
Complementarity with national level data 
The participating national focal points from France, the Netherlands, Spain and Sweden presented the 
different models of national acute drug intoxication monitoring that are in place in their countries, and 
discussed their strengths and weaknesses in terms of routine monitoring and early warning systems on 
drug-related harm. 
There are notable differences in the nature and design of the monitoring systems in place across these 
countries. Most systems record only the number of acute drug toxicity presentations to hospital 
emergency departments, and sometimes only cases in which the patient is admitted (EMCDDA, 2014; 
Heyerdahl, 2014). However, other models exist, in particular the Dutch system (Monitor 
Drugsincidenten) and the Spanish system (Indicator of the Spanish Observatory on Drugs and 
Addiction), which are ‘based on multiple indicators, allowing broad coverage of different catchment 
areas, settings (emergency departments, ambulance services, forensic services, first aid stations at 
dance parties) and types of drug use. These systems contribute to monitoring new trends, in particular 
in high-risk drug use, and to validating data from other indicators (including on treatment, deaths, drug 
checking and drug consumption rooms). 
In the Netherlands, the national system is also instrumental in the initiation of drug-related ‘red alert’ 
procedures. Similarly, in France, real-time data from hospital surveillance, collection of which began in 
2003, are valuable to the national early warning system on drugs. In addition to revealing long-term 
trends and providing good coverage (capturing 9 out of 10 emergency department visits in France), the 
system is also relatively cheap and simple, based on automated extraction of data from patients’ 
electronic medical records. However, a weakness of the system is a lack of sensitivity due to coding 
limitations (see Wood et al., 2011, 2019). Another weakness of the French system and other systems 
for routine national data collection compared with the collection of data from sentinel emergency 
departments is a lack of precision regarding the substances involved (especially for opioids) and a lack 
of clinical and outcome information. Furthermore, in many countries the systems are based on 
retrospective data extraction and thus not suitable for informing early warning systems. 
In several countries, such as Sweden, there is not yet any systematic collection of data from hospitals, 
poison centres or other emergency settings, but discussions on implementing relevant systems are 
under way. 
Synergies with Euro-DEN Plus could be explored, in particular where local (hospital, city or regional 
level) routinely collected data could be cross-checked against local Euro-DEN Plus figures. This could 
validate the routine data or contribute to estimating the extent of the invisible fraction of cases flagged 
by Euro-DEN Plus but missed in routine statistics. Other exploratory work could look at the possible 
complementarity of data from other sources, such as poison centres (Wood et al., 2014b). 
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Conclusions 
Every year in Europe, thousands of individuals suffer drug-related acute toxicity that requires hospital 
attendance. These drug-related hospital emergency presentations are most likely to occur in young 
adults and to involve heroin, cocaine and cannabis. Findings from Euro-DEN Plus also highlight the 
potentially considerable burden on health services but also the potential for interventions. Over three 
quarters of cases are brought to the emergency department by ambulance and, while most cases are 
discharged quickly, a small but significant minority (6 %) involve severe acute toxicity requiring critical 
care admission, and some deaths are reported among this cohort. It is also important to note that 
clinical features associated with significant medical and nursing staff input, such as agitation/psychosis, 
are commonly seen in these patients. This has clear implications from a resource and staffing 
perspective, particularly as these presentations are most common at weekends and in the late evening 
to early hours of the morning. 
Data on hospital emergency department presentations provide a unique insight into acute health harms 
related to drug use, complementing data from the EMCDDA key indicators and broadening the scope of 
monitoring of the health consequences of drug use. This is particularly important in the light of the 
limited systematic data reported on acute drug toxicity in Europe. Findings from the Euro-DEN Plus 
project help to increase understanding of the drugs responsible for acute toxicity in Europe, whether 
they are illicit substances, NPS or misused prescription medicines. This dataset also enables analysis 
of geographical and time trends, patterns of acute toxicity and the potential implications of these 
presentations. The data do not necessarily provide a nationally representative picture, as only selected 
sites in participating countries are included. However, the increasing size and geographical reach of 
Euro-DEN Plus helps to minimise this limitation. Using a number of sentinel sites in significant locations 
provides useful data on the drugs resulting in presentations to emergency departments in Europe and 
the trends in these drugs and these locations over time. 
Continuation and further development of work in this area will be important to enable a greater 
understanding of the acute harm associated with drug use in Europe. The next steps in the 
development of the Euro-DEN Plus project — in addition to continuing to recruit centres to increase the 
representativeness of the data — is to further consider triangulation of the Euro-DEN Plus dataset with 
key indicator and other complementary and developing drug datasets in Europe. This will help to inform 
delivery of appropriate healthcare and prevention activities and provide a more complete picture to 
legislative and public health bodies of the overall implications of drug use for the European population. 
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Appendices 
 
Appendix 1: Number of presentations by centre and by year, Euro-DEN Plus, 
2014-17 
Country  City 2014 2015 2016 2017 Total  
Denmark Copenhagen 155       155 
 Roskilde   89 66  155 
Estonia Pärnu 13 31 28 25 97 
  Tallinn 115 91 97 113 416 
France Paris 377 261 243 273 1,154 
Germany Munich 213 152 115 113 593 
Ireland Drogheda 29 11 24 20 84 
  Dublin 524 543 436 586 2,089 
Norway Oslo OAEOC 1,529 1,576 1,303 1,593 6,001 
  Oslo OUH 192 180 194 196 762 
Poland Gdańsk 158 236 125 103 622 
Spain Barcelona 182 108 147 224 661 
  Mallorca 190 237 249 350 1,026 
United Kingdom London STH 934 921 960 1,040 3,855 
London KCH 405 439 379 434 1,657 
York 204 180 124 76 584 
Switzerland Basel 224 210 244 275 953 
  Bern     206 259 465 
  Lugano 
      
105 
(from July) 
105 
Bulgaria Sofia 
    
49 
(from May) 
87 136 
Czechia Prague      26 26 52 
Malta Msida     218 369 587 
Slovakia Bratislava     91 56 147 
Belgium  Antwerp       500 500 
Ghent       113 113 
Finland Helsinki       253 253 
Georgia Tbilisi 
      
8 
(from May) 
8 
Italy Monza       113 113 
Latvia Riga       81 81 
Lithuania Kaunas       164 164 
  Vilnius       203 203 
Slovenia Ljubljana       156 156 
Total    5,444 5,265 5,324 7,914 23,947 
Note: Ordered by year when participation began and country. 
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Appendix 2: Number of presentations related to selected drugs, by centre, Euro-
DEN Plus, 2017 
Country City 
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Belgium Antwerp 37 157 111 69 53 8 42 1 4 500 
 Ghent 5 37 43 26 15 8 16 4 1 113 
Bulgaria Sofia  9 13 45 22 2 8 0 3 0 87 
Czechia Prague  1 1 5 3 6 0 1 4 1 26 
Estonia Pärnu 0 1 8 9 8 0 4 9 0 25 
  Tallinn 1 13 19 35 11 5 39 10 0 113 
Finland Helsinki 2 4 17 38 6 4 110 3 8 253 
France Paris 13 70 82 8 51 23 15 4 9 273 
Georgia Tbilisi 0 0 2 0 0 0 0 0 2 8 
Germany Munich 7 8 12 12 3 9 2 8 20 113 
Ireland Drogheda 0 10 6 0 7 0 0 1 0 20 
  Dublin 199 120 58 4 41 45 9 4 9 586 
Italy Monza 11 61 56 3 0 3 0 2 0 113 
Latvia Riga 9 5 13 7 1 8 2 5 3 81 
Lithuania Kaunas 12 3 13 5 5 6 0 1 6 164 
 Vilnius 98 9 31 19 1 8 3 6 16 203 
Malta Msida 93 166 103 2 17 1 1 0 92 369 
Norway Oslo OAEOC 524 99 227 380 67 71 196 11 1 1,593 
  Oslo OUH 27 13 13 33 9 2 104 1 0 196 
Poland Gdańsk 1 9 19 26 4 1 2 3 54 103 
Slovakia Bratislava 0 8 27 3 9 0 0 25 2 56 
Slovenia Ljubljana 21 48 28 10 11 25 15 3 6 156 
Spain Barcelona 2 102 52 49 12 1 56 25 4 224 
  Mallorca 47 180 139 26 23 2 1 3 3 350 
Switzerland Basel 27 112 117 12 12 16 8 2 1 275 
 Bern 51 101 81 35 9 7 9 1 2 259 
 Lugano 8 39 47 2 0 3 0 0 0 105 
United Kingdom London STH 132 200 97 11 122 37 214 154 205 1,040 
  London KCH 62 90 60 12 58 5 106 68 29 434 
  York 18 21 19 3 19 6 1 0 4 76 
Total  1,417 1,700 1 550 864 582 312 956 361 482 7,914 
Note: Ordered by country and by centre, 2017. A presentation may involve more than one drug and therefore the numbers of 
presentations by drug do not add up to the total number of presentations in the far left column. 
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Appendix 3: Euro-DEN Plus centres and contributors, 2014-19 
 
Country Institution and contributors 
Belgium ZNA Stuivenberg, Antwerp, Belgium — Kurt Anseeuw, Johan Gillebeert 
Belgium Ghent University Hospital, Ghent, Belgium — Cathelijne Lyphout, Ibolya Toth, 
Laurence Daveloose 
Bulgaria University Hospital for Emergency Medicine N. I. Pirogov, Sofia, Bulgaria — Julia 
Radenkova-Saeva 
Czechia Czech Toxicological Information Centre, Prague, Czechia — Sergej Zacharov, Jan 
Rulisek, Zuzana Kolpach 
Denmark Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark — 
Gesche Jurgens, Bue Fogh Juvik, Kenneth Skov 
Estonia Emergency Department, Pärnu Hospital, Pärnu, Estonia — Raido Paasma 
Estonia Emergency Medicine Department, North Estonia Medical Centre, Tallinn, Estonia — 
Kristiina Põld 
Finland Malmi Hospital, Helsinki, Finland — Jutta Konstari 
France Emergency Department, Lariboisière Hospital, Paris-Diderot University, Paris, 
France — Bruno Megarbane, Lucie Chevillard, Karim Jaffal 
Georgia Archangel St Michael Multiprofile Clinical Hospital, Tbilisi, Georgia — Soso 
Kutubidze, Ketevan Gorozia 
Germany Department of Clinical Toxicology, Technical University of Munich, Munich, 
Germany — Florian Eyer, Stefanie Geith, Christian Rabe, Tobias Zellner 
Ireland Emergency Department, Our Lady of Lourdes Hospital, Drogheda, Ireland — Niall 
O’ Connor, Gerard Markey, Sarah-Jane Yeung, Radhika Sopirala, Paddy Hillery 
Ireland Emergency Department, Mater Misericordiae University Hospital, Dublin, Ireland — 
Adrian Moughty, Sinead Kilgarrif, Iarlaith Kennedy 
Italy San Gerardo Hospital (UOS Pronto Soccorso), ASST Monza, Italy — Federico 
Vigorita 
Latvia Riga East Clinical University Hospital, Riga, Latvia — Roberts Stašinskis, Viesturs 
Liguts 
Lithuania The Hospital of Lithuanian University of Health Sciences, Kauno Klinikos, Kaunas, 
Lithuania — Jonas Surkus, Marius Perminas 
Lithuania Republic Vilnius University Hospital, Vilnius, Lithuania — Gabija Laubner, Robertas 
Badaras 
Malta Clinical Toxicology Lead Mater Dei Hospital, Valletta, Malta — Jeffrey Bonnici 
Netherlands Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands — Femke Gresnigt 
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Netherlands Dutch Poisons Information Centre, University Medical Centre Utrecht, the 
Netherlands — Laura Hondebrink, Irma van den Hengel-Koot 
Norway Department of Acute Medicine, Oslo University Hospital, Oslo, Norway — Knut Erik 
Hovda, Fridtjof Heyerdahl, Per Sverre Persett 
Norway Oslo Accident and Emergency Outpatient Clinic, City of Oslo Health Agency, 
Norway — Odd Martin Vallersnes 
Poland Pomeranian Centre of Clinical Toxicology, Medical University of Gdańsk, Gdańsk, 
Poland — Jacek Anand, Piotr Kabata, Wojciech Waldman  
Romania Children’s Hospital Grigore Alexandrescu, Bucharest, Romania — Viorela Nitescu 
Slovakia National Toxicological Information Centre, University Hospital Bratislava, Slovakia — 
Blazena Caganova 
Slovenia Centre for Clinical Toxicology & Pharmacology, University Medical Centre Ljubljana, 
Slovenia — Miran Brvar, Damjan Grenc 
Spain Emergency Area, Clinical Toxicology Unit, Hospital Clinic, Barcelona, Spain — 
Òscar Miró, Miguel Galicia 
Spain Emergency Department and Clinical Toxicology Unit, Hospital Universitari Son 
Espases, Mallorca, Spain — Chris Yates, Jordi Puiguriguer, Catalina Homar, Juan 
Ortega Perez 
Switzerland Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, 
Switzerland — Matthias Liechti, Yasmin Schmid 
Switzerland Clinical Pharmacology and Toxicology, University Hospital Bern, Switzerland — 
Evangelia Liakoni, Irene Scholz 
Switzerland Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero 
Cantonale, Lugano, Switzerland — Alessandro Ceschi, Laura Müller, Roberta 
Noseda 
United Kingdom Clinical Toxicology and Emergency Department, St Thomas’ Hospital, Guy’s and St 
Thomas’ NHS Foundation Trust and King’s Health Partners, London, United 
Kingdom — Paul Dargan, David Wood, Alison Dines, John Archer, Takahiro 
Yamamoto, Luke de la Rue, Kerry Layne, Craig Leaper, Caitlin Wolfe, Grainne 
Cullen 
United Kingdom Emergency Department, Kings College Hospital, King’s College Hospital NHS 
Foundation Trust and King’s Health Partners, London, United Kingdom — Paul 
Dargan, David Wood, Alison Dines, Melvin Lipi 
United Kingdom Emergency Department, York Hospital, York Teaching Hospital NHS Foundation 
Trust, York, United Kingdom — Stephen Waring 
 
